A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial

Overview of attention for article published in European Journal of Cancer (1965), April 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 3 news outlets
policy: 2 policy sources

patent: 2 patents
guideline: 2 clinical guideline sources

Readers on

mendeley: 57 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

CytRx's Aldoxorubicin Phase 3 Trial: A High EV Scenario

Seeking Alpha, 29 Jun 2016

Clinical Activity of Aldoxorubicin Monotherapy There are any number of adjuvant tries in clinical oncology today.

FDA Approves Trabectedin (Yondelis) for Advanced Soft-Tissue Sarcoma

UBM Medica, 26 Oct 2015

The US Food and Drug Administration announced the approval of trabectedin (Yondelis) for the treatment of liposarcoma and…

Sarcoma dei tessuti molli, trabectedina non frena la progressione [OncoEmato]

Pharmastar Italy, 21 May 2015

In uno studio di fase IIb pubblicato di recente online sullo European Journal of Cancer, trabectedina non è riuscita a…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.